Colchicine Prophylaxis for Gout Flares Linked to Lower Cardiovascular Events

Published Date: 22 Dec 2024

Colchicine Prophylaxis for Gout Flares Linked to Lower Cardiovascular Events

Read Full News

Latest News

Lupus Can Cost Young Women More Years Than Diabetes, HIV

Lupus contributes substantially to premature mortality in young women, with over 304,000 years of potential life lost in women aged 15-44 years from 2000 to 2015.

Pulmonary Fibrosis Video Diaries: Patient Experiences and Timely Diagnosis of IPF

Pulmonary Fibrosis Video Diaries: Patient Experiences and Timely Diagnosis of IPF

From Evidence to Action: Practical Strategies for FcRn Therapy in gMG

From Evidence to Action: Practical Strategies for FcRn Therapy in gMG

Next-Gen Therapies for gMG: The Science and Support for FcRn Antagonists

Next-Gen Therapies for gMG: The Science and Support for FcRn Antagonists

Strategies for Personalized CIDP Care: Patient Selection, Treatment Transition, and FcRn Therapy

Strategies for Personalized CIDP Care: Patient Selection, Treatment Transition, and FcRn Therapy

Transforming CIDP Management: Early Diagnosis, Pathophysiology, and the Emerging Role of FcRn Antagonists

Transforming CIDP Management: Early Diagnosis, Pathophysiology, and the Emerging Role of FcRn Antagonists

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Lupus contributes substantially to premature mortality in young women, with over 304,000 years of potential life lost in women aged 15-44 years from 2000 to 2015.

Pulmonary Fibrosis Video Diaries: Patient Experiences and Timely Diagnosis of IPF

From Evidence to Action: Practical Strategies for FcRn Therapy in gMG

Next-Gen Therapies for gMG: The Science and Support for FcRn Antagonists

Strategies for Personalized CIDP Care: Patient Selection, Treatment Transition, and FcRn Therapy

Transforming CIDP Management: Early Diagnosis, Pathophysiology, and the Emerging Role of FcRn Antagonists

News All Time

Osteoarthritis: Promising Drug Therapy Flops

No help from diacerein in randomized trial

Another B-Cell Drug for Lupus Hits the Mark

Phase III results put obinutuzumab in line for approval

Europe Does Better Than U.S. in Treating Spondyloarthritis, Survey Data Suggest

American patients report more symptoms and mostly don't agree with doctors on how they've fared

Medicare Coverage Appears Spotty for Newer Rheumatoid Arthritis Meds

Advantage plans do a better job than standalone Part D policies, albeit with important gaps

ICE Chief Hospitalized; Metastatic Colon Cancer at Age 26; TENS for Fibromyalgia

Health news and commentary gathered by MedPage Today staff

Dyspnea in Woman With RA Reveals a Diaphragmatic Lipoma

MRI can help differentiate these benign soft-tissue masses from more aggressive liposarcomas

What Caused This Patient's Recurring Eye and Ear Inflammation?

Prompt diagnosis of this rare progressive autoimmune disease may help preserve hearing, eyesight

What Caused Left-Sided Hearing Loss in This 65-Year-Old Man?

Numerous diagnostic procedures revealed tophaceous gout affecting the middle ear

EULAR: Docs Should Push Hard on Physical Activity for Arthritis Patients

We have met the enemy and it's the sofa, updated guideline indicates

Rheumatic Disease Drugs Help COVID Virus Stick Around Longer, Study Suggests

Lengthy viral antigen persistence far more common, regardless of prior vaccination

Drug Targeting TLRs in Cutaneous Lupus Looks Good in Mid-Stage Studies

— Dose-response signal appears in phase II trial, and all doses are better than placebo

Upadacitinib After TNF Inhibitor Failure Improves RA Control

In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.

Early Anti-TNF to Prevent Difficult-to-Treat RA Gains Steam

The availability of TNF inhibitor biosimilars and the cost of treating ‘difficult-to-treat’ RA are making first-line TNF inhibition in early RA more attractive in the UK.

FDA Grants Breakthrough Therapy Designation to Ianalumab, First Potential Sjögren’s Targeted Therapy Victoria Johnson

Novartis plans to submit regulatory applications for ianalumab in early 2026.

FDA Updates Label for Reduced Osteoarthritis Risk With BEAR Implant Over ACL Reconstruction Victoria Johnson

FDA approves a label update for the BEAR implant, which was previously approved in 2020.

FDA Grants Priority Review to Efgartigimod, First Potential Therapy for Seronegative Myasthenia Gravis Victoria Johnson

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

Recommended News For You

Should the UK introduce targeted prostate cancer screening? The case for and against

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

Fear of hair loss might cause some to reject cancer treatment

Telemedicine services linked to reducing excess mortality

How the skin cancer virus outperforms the replication of host cells.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

Recommended Articles For You

Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts 

Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care 

Radiation in Oncology: Advances, Applications, and Accessibility 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.

1.

Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training

2.

Hemoglobin C: Understanding its Role in Sickle Cell Disease

3.

Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging

4.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

5.

The Growing Challenge of Haematological Malignancies in Older Adults

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

2.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot